Bacteromic Receives Conditional Decision on US Patent for BacterOMIC Microfluidic Chip

Scope Fluidics S.A. (WSE: Scope Fluidics S.A. (WSE: SCP), a biotechnology firm operating under the Venture Studio model and listed on the sWIG80 index, which in 2022 led the largest transaction in the history of the Polish life science market, has announced that the U.S. Patent and Trademark Office has made a provisional decision to award a patent entitled ‘Microfluidic Chip’ under BacterOMIC’s project. As per the procedure, the patent will be granted upon the payment of the necessary fees by Bacteromic, due by April 3, 2024.

  • The patent will grant Bacteromic exclusive rights to commercially utilize measurement cards for microbiological determinations in the United States, particularly for the identification of microorganisms and testing their susceptibility to antimicrobial agents.
  • Bacteromic already holds patents for the aforementioned measurement cards and their application methods in fifteen countries that are parties to the European Patent Convention, as well as in China.
  • BacterOMIC, the flagship medtech system developed by Scope Fluidics, employs groundbreaking technology dedicated to combating antibiotic-resistant bacteria, one of the most rapidly escalating medical threats globally.

Marcin Izydorzak, co-founder, major shareholder, and Vice Chairman of the Management Board at Scope Fluidics, stated: – We are consistently expanding the patent protection for our flagship project across strategic global markets. Ensuring intellectual property rights is a crucial element of the project’s value, particularly from the viewpoint of a potential acquirer of the BacterOMIC technology.

The BacterOMIC System addresses the escalating global medical threat posed by antibiotic-resistant bacteria. According to World Health Organization estimates, by 2050, the annual death toll from infections caused by drug-resistant microorganisms is expected to increase from 700,000 to 10 million, making it one of the leading causes of death worldwide.

The BacterOMIC technology aims to expedite and enhance the effectiveness of patient treatment by identifying the most accurately targeted therapies for individual patients. Within up to 16 hours, it can precisely assess the sensitivity of bacteria to all clinically significant antibiotics, providing physicians with extensive information about the specific pathogen. The test’s top-market informational capacity stands as a key competitive advantage among several others for the system.

Since 2021, BacterOMIC has held the European CE-IVD certification, authorizing its marketing within the European Union. Development of the system commenced in 2016, and in 2017, the dedicated company, Bacteromic sp. z o.o., was established. In 2019, the BacterOMIC project reached the semi-final in the prestigious American Association for Clinical Chemistry Disruptive Technology Award Competition.